Akers Biosciences, Inc.

129 articles about Akers Biosciences, Inc.

• Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate

  3/24/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced it will hold a conference call to discuss the licensing announcement with Premas Biotech for a Coronvirus vaccine candidate.

• Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech

  3/24/2020

  Established D-Crypt™ platform will be used to develop a proof-of-concept targeting three of the top five viral vaccine protein candidates for Coronavirus Current Regulatory environment could lead to expedited clinical trials Rapid commercial scale-up processes in place with Premas based on genetically engineered yeast platform

• Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation

  1/17/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that it reached a settlement agreement to settle two shareholder derivative actions: Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.) and Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.).

• Akers BioSciences Regains Compliance with Nasdaq Listing Standards

  12/11/2019

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, announced today that on December 10, 2019, it received notice from the Hearings Advisor of the Nasdaq Office of General Counsel

• Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering

  12/9/2019

  Akers Biosciences, Inc. announced the closing of its previously announced public offering of 613,500 common units at a public offering price of $4.00 per unit and 1,376,500 pre-funded units at a public offering price of $3.9999 per pre-funded unit, raising gross proceeds of $7.96 million, before deducting placement agent’s fees and other estimated offering expenses payable by Akers, assuming none of the preferred stock warrants issued in this offering are exercised.

• Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada

  12/6/2019

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced that Executive Chairman Christopher Schreiber will attend the “Hemp Industry Daily Forum” on Tuesday, December 10, 2019 as part of MJBizCon Week at the Las Vegas Convention Center in Las Vegas, Nevada.

• Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering

  12/5/2019

  Thorofare, New Jersey, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (the “Company” or “we”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the pricing of a public offering of 1,990,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one preferred stock warrant to purchase one share of Series C Convertible Preferred Stock. The units are being offered at a public offering price of $4.00 per unit. H.

• Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry

  12/5/2019

  Establishes Advisory Board appointing Bob Hoban and Michael Patterson

• Akers Biosciences, Inc. Announces One-for-Twenty Four Reverse Stock Split

  11/22/2019

  Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced that effective at 8:00 a.m. eastern standard time on Monday, November 25, 2019, the Company will effect a reverse stock split of its issued and outstanding common stock of no par value at a ratio of one (1) share of common stock for every twenty four (24) shares of common stock

• SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akers Biosciences, Inc. of Class Action Lawsuit and Upcoming Deadline -- AKER

  7/7/2018

  Pomerantz LLP announces that a class action lawsuit has been filed against Akers Biosciences, Inc. and certain of its officers.

• Akers Bio Announces Closing of $6,900,000 Public Offering

  12/22/2017

  The funds raised will be used for working capital, product development, marketing activities, expanding our internal sales organization and further developing sales channels and other capital expenditures.

• Akers Biosciences Prices $6,000,000 Public Offering

  12/19/2017

  Akers Biosciences today announces the pricing of an underwritten public offering with expected total gross proceeds of approximately $6,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

• Akers Biosciences Announces Q3 2017 Earnings

  11/15/2017

  Total revenues were $2.6 million compared with $4.0 million for the nine months ended September 30, 2016.

• Akers Biosciences’ UK Distributor Secures New Channel for Rapid Alcohol Breathalyzer

  11/14/2017

  The BreathScan Alcohol Detector is a proprietary, single-use, non-mechanical device that measures the user’s blood alcohol concentration in approximately 2 minutes, through a simple breath test.

• Akers Biosciences Announces Conference Call to Discuss Q3 2017 Earnings

  11/13/2017

  Management will be available during a question-and-answer session.

• Akers Biosciences Hires Medical Device Specialist To Lead US Sales And Distribution

  9/7/2017

• Akers Biosciences Announces Q2 2017 Earnings

  8/15/2017

• Akers Biosciences Announces Board Changes

  8/8/2017

• Akers Biosciences Announces Second Quarter Trading Update

  8/4/2017

• Akers Biosciences Announces Q1 2017 Earnings

  5/17/2017